An Introduction to SuperShot® PRP

An Introduction to SuperShot® PRP

By Dr. Mark Katakowski, Ph.D. President & Chief Science Officer Forever Labs

Since we launched SuperShot® we have had tremendous interest in the ability to concentrate extracellular vesicles (EVs) in platelet-rich plasma (PRP) therapy.

As a research scientist, I have been studying the therapeutic value of mesenchymal stem cells for 20 years, and exosomes for 10 years, and have developed therapies and filed patents employing both. Several years ago, I became aware of the use of PRP in orthobiologics and began to study and experiment with PRP systems and techniques. Based upon my research experience with exosomes, it struck me that these potent biological molecules were not being leveraged in PRP therapies that included them but didn’t concentrate them. As my PhD is in Medical Physics, I turned to physics for a solution. Thus, SuperShot® was born.

In this post, I will address the most asked questions about SuperShot® and give some deeper insight into the rationale and science behind it.


What is SuperShot® PRP?

SuperShot® PRP is a process that concentrates the plasma EVs in PRP. By performing one additional spin of the platelet-poor plasma (PPP), SuperShot® enables the precipitation of low-density lipid-based EVs. Many of the EVs concentrated by SuperShot® are exosomes.

All PRP contains EVs (including exosomes). Using SuperShot® in the PRP process increases the content of EVs by concentrating them.


Why doesn’t the standard PRP process concentrate extracellular vesicles?

EVs are not dense enough to be isolated by clinical centrifuges, which typically spin at speeds of 1000-5000 RPM. To precipitate EVs by centrifugation alone, speeds of >100,000 RPM are required, and it takes several hours. Standard PRP contains EVs, but they are not concentrated above the patient’s basal plasma levels by the normal PRP process.


How does SuperShot® work?

SuperShot employs a physics technique to change the dynamics of plasma centrifugation. The addition of polyethylene glycol (PEG) and a high-weight Dextran (Dex) to plasma creates an aqueous two-phase system that decreases the solubility of low-density lipids (such as EVs). The EVs can then readily be pelleted at tabletop centrifuge speeds.


Is SuperShot® solution included in the PRP?

No. The PEG/Dex in SuperShot® solution remains in the depleted PPP, which is discarded. Both the PEG and Dex remain soluble in the PPP. Only the pelleted EVs are added to the PRP.


Is SuperShot® PRP autologous?

Yes. The SuperShot® process concentrates EVs that are in the patient’s plasma. Just like concentrating platelets, SuperShot® concentrates what is already in the patient’s blood..


Are plasma extracellular vesicles a therapeutic component of PRP?

This is an open question. PRP is relatively new itself, and its therapeutic components are still being elucidated. However, there is pre-clinical evidence that suggests that plasma-derived EVs (which include exosomes) have therapeutic value. Here are some recent studies of plasma EVs in animals:


Could the therapeutic effect of plasma extracellular vesicles vary between patients?

Almost certainly. As mentioned above, the individual therapeutic components of PRP itself have not been well-established; however, there is evidence that the effect of PRP varies between patients. If plasma EVs underpin the effects of PRP, then this effect would be expected to vary between patients as well.

As all physicians that employ PRP are aware, different PRP systems and processes result in different PRP preparations. PRP preparations vary in concentrations of leukocytes, RBCs, platelets, proteins, etc., and these vary within the same preparation between patients.

The SuperShot® PRP process enables the concentration of EVs in the PRP preparation.

Most physicians that use PRP clinically believe that more clinical trials to test applications and various PRP preparations will improve PRP therapy. The new ability to concentrate the EV component in PRP preparation should warrant consideration in clinical investigations as well.


Why are plasma extracellular vesicles interesting?

EVs are released by cells that efficiently transfer their molecular cargo to other cells. Plasma is rich in exosomes, a type of EV, and it is known that exosomes mediate many physiological functions, including inflammation, angiogenesis, and wound healing. Exosomes contain non-coding RNAs (such as microRNAs) that have potent effect upon acceptor cells that take up the exosomes.

Unlike proteins that are used by cells as functional molecules, non-coding RNAs in exosomes can modulate gene expression in acceptor cells. For these reasons, exosomes have generated considerable clinical interest over the past decade, with hundreds of clinical trials testing their therapeutic application


What is the regulatory status of SuperShot® PRP?

PRP is considered a blood product, per the FDA guidance “Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use”; July 2020, Section V.A, pg. 22: “…for example, platelet rich plasma (PRP, blood taken from an individual and given back to the same individual as platelet rich plasma) is not an HCT/P under 21 CFR Part 1271 because it is a blood product.”

SuperShot® PRP is a PRP preparation, according to the FDA’s guidance as:

  1. It is a blood product
  2. It is autologous
  3. It is removed from an individual and implanted into the same individual in the same surgical procedure,
  4. It does not include intervening processing steps beyond rinsing, cleansing, sizing, or shaping, and
  5. It raises no additional risks of contamination and communicable disease transmission beyond that typically associated with surgery.

Please see a Memorandum from Enzyme Corporation and our position paper here.


Does the SuperShot® isolated fraction contain exosomes?

Yes. The plasma is rich in exosomes, and exosomes are EVs that range between 30-150nm in diameter. Many analyses have demonstrated that the SuperShot® isolated fraction is rich in exosomes; indeed, they may be the most abundant EV present. However, there are other EVs isolated by SuperShot® as well, some ranging up to 450nm in size. As an example, some of these EVs are likely platelet-derived microvesicles which are larger than exosomes. Some EVs are created by different processes, however the characterization of EVs is often dependent upon the context in which they are studied.

Exosomes are some of the best studied EVs, and they constitute a large portion, if not the majority of EVs isolated in the SuperShot® fraction. For this reason, we often speak to the exosomes isolated by SuperShot®. That said, the SuperShot® process isolates all low-density EVs from the PPP.


Closing thoughts…

I believe in the therapeutic value of PRP. I know many physicians that use it, and many people that have benefited from it as patients. I believe that the better the components of PRP are understood, and the more fidelity applied to the preparation, the more potential PRP will have clinically.

As a scientist, it excites me that physicians now can concentrate the EV fraction in their PRP preparation. It is my hope that PRP therapy and most importantly, patient outcomes, can be improved as a result